PDC line Pharma SAS announced that it has received 11.8 million in a round of funding led by existing investor Korea Investment Partners Co. Ltd. on December 6, 2021. The transaction included participation from new investors Alpha Holdings, Inc., Brain Asset Management Co., Ltd., Hansongneotech Co.,Ltd. and existing investors Noshaq S.A., Sambrinvest S.A., Federal Holding and Investment Company, SociÉTé RÉGionale D'investissement De Wallonie Sa and UTC 2019 Bio Venture Fund, a fund managed by UTC Investment Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
945 KRW | -6.71% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 27.75M | |
+15.76% | 58.69B | |
-17.76% | 15.09B | |
+17.21% | 11.54B | |
+27.37% | 8.87B | |
+47.24% | 8.61B | |
+3.41% | 8.52B | |
-8.45% | 8.33B | |
-11.93% | 7.76B | |
-15.34% | 6.78B |
- Stock Market
- Equities
- A117670 Stock
- News Alpha Holdings, Inc.
- PDC line Pharma SAS announced that it has received €11.8 million in funding from a group of investors